Skip to main content

General Counsel

The amounts reported represent the aggregate grant date fair value of the stock options awarded to our named executive officers during each year presented, calculated in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 14 of our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by our named executive officers upon the vesting or exercise of the stock options or any sale of the underlying shares of common stock. The reported amounts represent the aggregate grant date fair value of awards of RSUs and PRSUs granted in each year presented, computed in accordance with FASB ASC Topic 718, excluding the estimate of forfeitures not related to the performance-based vesting of PRSUs. Amounts reflect the fair value of each award based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. The grant date fair value of the PRSUs is based on the probable outcome of the vesting conditions as of the grant date. For fiscal 2021, the grant date fair value of all PRSUs at maximum performance achievement, including the long-term PRSUs granted to Messrs Burton and Nelli, are $707,481, $143,537, $685,383, $187,683, and $110,390 for Messrs Burton, Hunt, Nelli, Horstmeier, and Mr. Orenstein, respectively. Represents the cash amounts earned by our named executive officers under our short-term incentive plan (the Bonus Plan), based on our achievement of certain corporate performance goals. For a description of the Bonus Plan, see “Compensation Discussion and Analysis –Annual Performance-Based Incentives” above. For the 2021 year, the amounts reported represent matching contributions made by us under our 401(k) plan ($8,700 for Mr. Burton, $7,916 for Mr. Hunt, $8,700 for Mr. Nelli, $8,700 for Mr. Horstmeier, and $8,700 for Mr. Orenstein), executive life insurance premiums paid by us ($578 for Mr. Burton, $398 for Mr. Nelli, $1,450 for Mr. Horstmeier, and $771 for Mr. Orenstein), executive long-term disability insurance premiums paid by us ($1,769 for Mr. Nelli and $4,084 for Mr. Horstmeier), gift cards paid by us as part of a benefit provided to all team members ($142 for Mr. Hunt, $535 for Mr. Nelli, and $898 for Mr. Orenstein), and $150 for a one-time cash payment made to all team members that received the COVID-19 vaccination. As we were an emerging growth company as of December 31, 2019, Mr. Nelli was not a named executive officer for 2019; however, this information for 2019 is being included based on interpretive guidance from the Division of Corporation Finance. Mr. Hunt was not a named executive officer prior to 2021 and Mr. Orenstein was not a named executive officer prior to 2020.

Other

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Health Catalyst, Inc. (HCAT) $300,000 $1,519,532
2021 Health Catalyst, Inc. (HCAT) $300,000 $1,718,043
2020 Health Catalyst, Inc. (HCAT) $300,000 $1,710,044

Earnings-call appearances

No earnings-call appearances recorded yet.